Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 222

1.

AXL BLOCKADE BY BGB324 INHIBITS BCR-ABL TYROSINE KINASE INHIBITOR-SENSITIVE AND -RESISTANT CHRONIC MYELOID LEUKEMIA.

Ben Batalla I, Erdmann R, Jørgensen H, Mitchell R, Ernst T, von Amsberg G, Schafhausen P, Velthaus JL, Rankin S, Clark RE, Koschmieder S, Schultze A, Mitra S, Vandenberghe P, Brümmendorf TH, Carmeliet P, Hochhaus A, Pantel K, Bokemeyer C, Helgason GV, Holyoake TL, Loges S.

Clin Cancer Res. 2016 Nov 17. pii: clincanres.1930.2016. [Epub ahead of print]

PMID:
27856601
2.

Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)-report on phases I and II.

Groth M, Singer S, Niedeggen C, Petermann-Meyer A, Röth A, Schrezenmeier H, Höchsmann B, Brümmendorf TH, Panse J.

Ann Hematol. 2016 Nov 11. [Epub ahead of print]

PMID:
27837250
3.

[(Pan-)cytopenia as first manifestation of kryptic telomeropathies in adults].

Schmitt K, Beier F, Panse J, Brümmendorf TH.

Dtsch Med Wochenschr. 2016 Oct;141(21):1578-1580. German.

PMID:
27750347
4.

A three-gene expression-based risk score can refine the European LeukemiaNet AML classification.

Wilop S, Chou WC, Jost E, Crysandt M, Panse J, Chuang MK, Brümmendorf TH, Wagner W, Tien HF, Kharabi Masouleh B.

J Hematol Oncol. 2016 Sep 1;9(1):78. doi: 10.1186/s13045-016-0308-8.

5.

CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo.

Mladenov R, Hristodorov D, Cremer C, Gresch G, Grieger E, Schenke L, Klose D, Amoury M, Woitok M, Jost E, Brümmendorf TH, Fendel R, Fischer R, Stein C, Thepen T, Barth S.

Oncotarget. 2016 Aug 24. doi: 10.18632/oncotarget.11568. [Epub ahead of print]

6.

Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.

Cortes JE, Khoury HJ, Kantarjian HM, Lipton JH, Kim DW, Schafhausen P, Matczak E, Leip E, Noonan K, Brümmendorf TH, Gambacorti-Passerini C.

Am J Hematol. 2016 Dec;91(12):1206-1214. doi: 10.1002/ajh.24536.

PMID:
27531525
7.

Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians.

Kaifie A, Isfort S, Gattermann N, Hollburg W, Klausmann M, Wolf D, Maintz C, Hänel M, Goekkurt E, Göthert JR, Platzbecker U, Geer T, Parmentier S, Jost E, Serve H, Ehninger G, Berdel WE, Brümmendorf TH, Koschmieder S; Study Alliance Leukemia (SAL)..

Ann Hematol. 2016 Sep;95(9):1399-410. doi: 10.1007/s00277-016-2730-y.

PMID:
27334946
8.

γ-Glutamyl Transferase Is an Independent Biomarker of Splanchnic Thrombosis in Patients With Myeloproliferative Neoplasm.

Görtzen J, Hunka LM, Vonnahme M, Praktiknjo M, Kaifie A, Fimmers R, Jansen C, Heine A, Lehmann J, Goethert JR, Gattermann N, Goekkurt E, Platzbecker U, Brossart P, Strassburg CP, Brummendorf TH, Koschmieder S, Wolf D, Trebicka J.

Medicine (Baltimore). 2016 May;95(20):e3355. doi: 10.1097/MD.0000000000003355.

9.

Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion.

Han L, Schubert C, Köhler J, Schemionek M, Isfort S, Brümmendorf TH, Koschmieder S, Chatain N.

J Hematol Oncol. 2016 May 13;9(1):45. doi: 10.1186/s13045-016-0275-0.

10.

Accelerated telomere shortening in peripheral blood lymphocytes after occupational polychlorinated biphenyls exposure.

Ziegler S, Schettgen T, Beier F, Wilop S, Quinete N, Esser A, Masouleh BK, Ferreira MS, Vankann L, Uciechowski P, Rink L, Kraus T, Brümmendorf TH, Ziegler P.

Arch Toxicol. 2016 May 5. [Epub ahead of print]

PMID:
27146145
11.

Combined Population Dynamics and Entropy Modelling Supports Patient Stratification in Chronic Myeloid Leukemia.

Brehme M, Koschmieder S, Montazeri M, Copland M, Oehler VG, Radich JP, Brümmendorf TH, Schuppert A.

Sci Rep. 2016 Apr 6;6:24057. doi: 10.1038/srep24057.

12.

Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib.

Cortes JE, Jean Khoury H, Kantarjian H, Brümmendorf TH, Mauro MJ, Matczak E, Pavlov D, Aguiar JM, Fly KD, Dimitrov S, Leip E, Shapiro M, Lipton JH, Durand JB, Gambacorti-Passerini C.

Am J Hematol. 2016 Jun;91(6):606-16. doi: 10.1002/ajh.24360.

PMID:
26971533
13.

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry.

Kaifie A, Kirschner M, Wolf D, Maintz C, Hänel M, Gattermann N, Gökkurt E, Platzbecker U, Hollburg W, Göthert JR, Parmentier S, Lang F, Hansen R, Isfort S, Schmitt K, Jost E, Serve H, Ehninger G, Berdel WE, Brümmendorf TH, Koschmieder S; Study Alliance Leukemia (SAL)..

J Hematol Oncol. 2016 Mar 5;9:18. doi: 10.1186/s13045-016-0242-9.

14.

The IL-33/ST2 pathway contributes to intestinal tumorigenesis in humans and mice.

Mertz KD, Mager LF, Wasmer MH, Thiesler T, Koelzer VH, Ruzzante G, Joller S, Murdoch JR, Brümmendorf T, Genitsch V, Lugli A, Cathomas G, Moch H, Weber A, Zlobec I, Junt T, Krebs P.

Oncoimmunology. 2015 Jun 26;5(1):e1062966.

15.

Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH).

Appelmann I, Kreher S, Parmentier S, Wolf HH, Bisping G, Kirschner M, Bergmann F, Schilling K, Brümmendorf TH, Petrides PE, Tiede A, Matzdorff A, Griesshammer M, Riess H, Koschmieder S.

Ann Hematol. 2016 Apr;95(5):707-18. doi: 10.1007/s00277-016-2621-2. Review.

PMID:
26916570
16.

DNA methylation in PRDM8 is indicative for dyskeratosis congenita.

Weidner CI, Lin Q, Birkhofer C, Gerstenmaier U, Kaifie A, Kirschner M, Bruns H, Balabanov S, Trummer A, Stockklausner C, Höchsmann B, Schrezenmeier H, Wlodarski M, Panse J, Brümmendorf TH, Beier F, Wagner W.

Oncotarget. 2016 Mar 8;7(10):10765-72. doi: 10.18632/oncotarget.7458.

17.

Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9.

Schneider RK, Schenone M, Ferreira MV, Kramann R, Joyce CE, Hartigan C, Beier F, Brümmendorf TH, Germing U, Platzbecker U, Büsche G, Knüchel R, Chen MC, Waters CS, Chen E, Chu LP, Novina CD, Lindsley RC, Carr SA, Ebert BL.

Nat Med. 2016 Mar;22(3):288-97. doi: 10.1038/nm.4047.

18.

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV.

Miranda MB, Lauseker M, Kraus MP, Proetel U, Hanfstein B, Fabarius A, Baerlocher GM, Heim D, Hossfeld DK, Kolb HJ, Krause SW, Nerl C, Brümmendorf TH, Verbeek W, Fauser AA, Prümmer O, Neben K, Hess U, Mahlberg R, Plöger C, Flasshove M, Rendenbach B, Hofmann WK, Müller MC, Pfirrmann M, Hochhaus A, Hasford J, Hehlmann R, Saußele S.

Leukemia. 2016 Jun;30(6):1255-62. doi: 10.1038/leu.2016.20.

19.

An engineered multicomponent bone marrow niche for the recapitulation of hematopoiesis at ectopic transplantation sites.

Ventura Ferreira MS, Bergmann C, Bodensiek I, Peukert K, Abert J, Kramann R, Kachel P, Rath B, Rütten S, Knuchel R, Ebert BL, Fischer H, Brümmendorf TH, Schneider RK.

J Hematol Oncol. 2016 Jan 25;9:4. doi: 10.1186/s13045-016-0234-9.

20.

MicroRNA expression profiles of serum from patients before and after chemotherapy.

Diener Y, Walenda T, Jost E, Brümmendorf TH, Bosio A, Wagner W, Bissels U.

Genom Data. 2015 Sep 2;6:125-7. doi: 10.1016/j.gdata.2015.08.018.

Items per page

Supplemental Content

Loading ...
Support Center